YURiA-PHARM strengthens its presence in Uzbekistan: company ranks No. 2 in the market, Reosorbilact and Tivortin top the brand ranking
Over the past decade, YURiA-PHARM has established a strong market position in Uzbekistan, becoming one of the country’s leading pharmaceutical companies. Two of its products have taken the top positions in the national pharmaceutical brand ranking, while the next stage of the company’s development is focused on deepening its local manufacturing presence.
According to Proxima Research, based on MAT data for August 2025 to July 2026, YURiA-PHARM ranks No. 2 among pharmaceutical companies in Uzbekistan’s retail pharmaceutical market. The company’s sales during this period reached $65.4 million, representing a 3.0% market share. The top two positions in the national pharmaceutical brand ranking are held by YURiA-PHARM products Reosorbilact and Tivortin. Both medicines are used in infusion therapy, an area in which the company has been building its expertise for decades.
Today, these products are widely used in medical practice in Uzbekistan, including in inpatient care for patients in severe and critical conditions, as well as in conditions requiring infusion therapy. The leading positions of Reosorbilact and Tivortin are not only a commercial achievement. They also reflect the scale of the company’s products’ presence in everyday clinical practice and the demand for solutions that YURiA-PHARM continues to develop and make available to physicians and patients in Uzbekistan.
At the same time, YURiA-PHARM’s development in the country is no longer limited to the presence of its products on the market. In 2023, the Reka-Med Farm manufacturing site became part of the Group. Its modernization made it possible to increase the target production capacity by approximately 50%, to 13.5 million units per year. The site already manufactures a number of YURiA-PHARM medicines, including Reosorbilact and Tivortin.
The scale of the business built over the past decade is now being further strengthened through the development of local manufacturing. For YURiA-PHARM, this marks the next stage of its presence in Uzbekistan: moving from a strong position in the pharmaceutical market toward deeper integration into the country’s pharmaceutical industry.
